Showing results (871-880 of 951) with videos related to

Sort By:
Pageof 96
Infection and Immunity|August 18, 2010
New candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1Anna L Goodman, C Epp, D Moss, et al.
Human Vaccines & Immunotherapeutics|November 13, 2012
Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trialRosalind Rowland, Ansar A Pathan, Iman Satti, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 24, 2012
Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humansPatrick J Lillie, Tamara K Berthoud, Timothy J Powell, et al.
Nature Communications|October 8, 2021
ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7Robert J Fischer, Neeltje van Doremalen, Danielle R Adney, et al.
ACS Central Science|May 31, 2021
Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 VaccineYasunori Watanabe, Luiza Mendonça, Elizabeth R Allen, et al.
Scientific Reports|February 23, 2018
Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAPCarly M Bliss, Georgina Bowyer, Nicholas A Anagnostou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 18, 2025
Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase III trials of docetaxel and zoledronic acid using healthcare systems dataC Jones, P Dutey-Magni, L R Murphy, et al.
Science Translational Medicine|July 28, 2021
Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical modelsNeeltje van Doremalen, Jyothi N Purushotham, Jonathan E Schulz, et al.
The Lancet. Microbe|November 9, 2021
Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trialMohammad Bosaeed, Hanan H Balkhy, Sultan Almaziad, et al.
Biorxiv : the Preprint Server for Biology|January 27, 2021
Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccineYasunori Watanabe, Luiza Mendonça, Elizabeth R Allen, et al.
Pageof 96